Name | (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone |
Synonyms | Dapagliflozin Impurity 18 Dapagliflozin Intermediate I 5-bromo-2-chloro-4'-ethoxybenzophenone (5-Brom-2-chlorphenyl)(4-ethoxyphenyl)methanon (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone |
CAS | 461432-22-4 |
EINECS | 630-623-9 |
InChI | InChI=1/C15H12BrClO2/c1-2-19-12-6-3-10(4-7-12)15(18)13-9-11(16)5-8-14(13)17/h3-9H,2H2,1H3 |
Molecular Formula | C15H12BrClO2 |
Molar Mass | 339.61 |
Density | 1.438g/cm3 |
Boling Point | 439.162°C at 760 mmHg |
Flash Point | 219.397°C |
Vapor Presure | 0mmHg at 25°C |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 1.592 |
Use | Uses (5-bromo-2-chlorophenyl) (4-ethoxyphenyl) ketone is an intermediate used to improve the synthesis of dapagliflozin, a novel selective type II sodium-glucose cotransporter (SGLT2) inhibitor. |
Downstream Products | 4-(5-broMo-2-chlorobenzyl)phenol |
(5-bromo-2-chlorophenyl) (4-ethoxyphenyl) ketone, also known as 5-bromo-2-chloro-4'-ethoxybenzophenone, is a key intermediate in the synthesis of dapagliflozin. Dapagliflozin (Dapagliflozin) is a new anti-diabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca. It is the first SGLT2 inhibitor approved for the treatment of type 2 diabetes. As an important choice in the treatment of diabetes, it is suitable for adults with type 2 diabetes as an auxiliary diet and exercise to improve blood sugar control.